Devlin H, Greenwall-Cohen J, Benton J, Goodwin T L, Littlewood A, Horner K
Division of Dentistry, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PL, UK.
General Dental practitioner, Bloxham Dental Practice, Godswell Stables, Bloxham, OX15 4ES, UK.
Br Dent J. 2018 Jan;224(1):26-31. doi: 10.1038/sj.bdj.2017.1001. Epub 2017 Nov 17.
Introduction Oral bisphosphonates are the most commonly prescribed anti-resorptive drugs used in the treatment of osteoporosis, but osteonecrosis of the jaw is a serious complication. The early diagnosis of this destructive side effect is crucial in preventing excessive bone loss, pain and infection.Objective To aid dental practitioners in the early identification of bisphosphonate-related osteonecrosis of the jaw.Method A scoping review was carried out.Data sources We searched MEDLINE via OVID, EMBASE via OVID, Dentistry and Oral Sciences Source (DOSS), Proquest Dissertation and Theses Search, to identify references that described clinical and radiological findings in medication-related osteonecrosis of the jaw (MRONJ).Data selection Nineteen references mentioned the earliest radiological changes in MRONJ with a description of the observations and were included in the analysis.Data synthesis The radiographic signs included osteosclerosis/lysis, widening of the periodontal ligament and thickening of the lamina dura and cortex. To assess the quality of original data on which recommendations had been made, these 19 studies were subjected to a quality appraisal.Conclusion Using bone exposure as a criterion for diagnosis of MRONJ, leads to delayed diagnosis and a poor response to treatment. In those patients at risk of bone exposure with MRONJ, insufficient information is present in the literature to allow the general dental practitioner to reliably identify the radiographic features indicating imminent bone exposure. A well-designed prospective study is needed.
引言
口服双膦酸盐是治疗骨质疏松症最常用的抗吸收药物,但颌骨坏死是一种严重的并发症。早期诊断这种破坏性副作用对于预防过度骨质流失、疼痛和感染至关重要。
目的
帮助牙科医生早期识别双膦酸盐相关颌骨坏死。
方法
进行了一项范围综述。
数据来源
我们通过OVID检索了MEDLINE、通过OVID检索了EMBASE、检索了牙科与口腔科学来源数据库(DOSS)、Proquest学位论文与学术论文搜索库,以识别描述药物相关颌骨坏死(MRONJ)临床和影像学表现的参考文献。
数据选择
19篇参考文献提到了MRONJ最早的影像学变化,并对观察结果进行了描述,纳入分析。
数据综合
影像学征象包括骨硬化/骨质溶解、牙周膜增宽以及硬骨板和皮质增厚。为评估做出推荐所依据的原始数据质量,对这19项研究进行了质量评估。
结论
以骨暴露作为MRONJ的诊断标准会导致诊断延迟且治疗反应不佳。在有MRONJ骨暴露风险的患者中,文献中缺乏足够信息,无法让普通牙科医生可靠地识别提示即将发生骨暴露的影像学特征。需要开展精心设计的前瞻性研究。